Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - glucose, quantity: 500 mg/ml - injection, solution - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) indications as at 20 may 1996 : sever hypoglycaemia resulting from insulin excess. glucose injection (50%) is strongly hypertonic and may be used for its dehydrating effects. being hypertonic, it is administered to promote diuresis, reduce increased cerebrospinal pressure and or impending cerebral oedema due to delirium tremens or acute alcoholic intoxication, glucose (50%) may also be used as a sclerosing agent in the treatment of varicose veins, however recanalisttion and pulmonary embolism are likely to occur.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - azovan blue, quantity: 5 mg/ml - injection, solution - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) for the determination of circulating plasma volume.

Australia - English - Department of Health (Therapeutic Goods Administration)

opthalmico pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 61006 - humeral stem extension prosthesis - composed of tial6v4 with silver coating. the connection piece consists of two parts: the mutars connecting part distal & connecting part proximal. the two parts are connected with the mutars screw for connecting part. uses the mutars cylindrical fit & serration connection for attachment to the mutars humerus head, reducer piece, connecting part, end piece, stem, distal humerus & proximal ulna. the connecting part has 1 retention ring for securing a pet mesh soft tissue attachment tube. a component of the mutars system intended as an extraosseous length adjustment in the area of the humerus for the bridging of bone defects. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis. the silver coated surface builds a long term prophylaxis against the colonisation of human pathogenic bacteria such as staphylococcus aureus and epidermis, exclusive enterobacteriae and should not be considered as acute treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 61561 - body femoral/tibial extension stem, uncoated - composed of tial6v4 with silver anti-infective coating. consists of two parts: the mutars connecting part distal & mutars connecting part proximal. the two parts are connected to each other with the mutars screw for connecting part. utilizes the mutars cylindrical fit & serration connection design for attachment to the distal femur or modular proximal tibia component and a femoral or tibial stem. the connecting part has 1 retention ring for securing a pet mesh soft tissue attachment tube. a component of the mutars system intended to be sued as an extraosseous length adjustment in the area of the distal femur or proximal tibia for the bridging of bone defects. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis. the silver coated surface builds a long term prophylaxis against the colonisation of human pathogenic bacteria such as staphylococcus aureus and epidermis, exclusive enterobacteriae and should not be considered as acute treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 33692 - rotating hinged total knee prosthesis - composed of tial6v4 with silver anti-infective coating. to be combined with the mutars modular proximal tibia to bridges bone defects in the area of the proximal tibia. design has a retention ring for securing a pet mesh soft tissue attachment tube. the connecting part is attached to the modular proximal tibia component by the means of two screws. the distal end of the connecting part provides a cylindrical fit connection for connecting with a tibial stem and/or extension piece(s). a component of the mutars system intended to be used as a component of a replacement for the proximal section of the tibia as part of a total knee replacement or revision. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis. the silver coated surface builds a long term prophylaxis against the colonisation of human pathogenic bacteria such as staphylococcus aureus and epidermis, exclusive enterobacteriae and should not be considered as acute treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 58084 - diaphysis prosthesis - composed of tial6v4 with silver anti-infective coating. a component of the mutars (modular universal tumor and revision) system. connects between the mutars diaphyseal implant and an extension piece or directly to a femoral stem. a connecting part for a diaphyseal implant to bridge diaphyseal bone defects of the femoral bone with a silver coating to prevent infection and colonisation of the implant. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis. the silver coated surface builds a long term prophylaxis against the colonisation of human pathogenic bacteria such as staphylococcus aureus and epidermis, exclusive enterobacteriae and should not be considered as acute treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - cupric chloride dihydrate, quantity: 560 microgram/ml (equivalent: copper, qty 200 microgram/ml); manganese chloride tetrahydrate, quantity: 740 microgram/ml (equivalent: copper, qty 200 microgram/ml; equivalent: manganese, qty 200 microgram/ml); chromic chloride hexahydrate, quantity: 22 microgram/ml (equivalent: copper, qty 200 microgram/ml; equivalent: chromium, qty 4 microgram/ml) - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - indications as at 01 january 1991 : this formulation is indicated for use as a supplement to iv solutions given for tpn. administation of the solution in tpn solutions helps to maintain plasma levels of copper, manganese, and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium nitrite, quantity: 30 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 18 may 2005 : sodium nitrite injection is indicated for the treatment of cynanide poisoning.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - zinc sulfate, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: - indications as at 01 dec 1998 : zinc sulphate injection is intended for use as an additive to compatible intravenous fluids or total parenteral nutrition solutions. it is indicated for the prevention and treatment of zinc deficiency, which may be characterised by growth deterioration, skin lesions, alopecia, impaired reproductive development and function, and delayed or inhibited wound healing.